The deputy director and chief of stem cell transplantation at Miami Cancer Institute discussed the study of axicabtagene ciloleucel vs tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma.
Guenther Koehne, MD, PhD
Advertisement
Articles by Guenther Koehne, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Picks Abeona’s XLRS Gene Therapy ABO-503 for RDEA Pilot Program
2
Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation
3
BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again
4
